vs
Aclaris Therapeutics, Inc.（ACRS）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
Aclaris Therapeutics, Inc.的季度营收约是Arcadia Biosciences, Inc.的1.4倍（$1.3M vs $901.0K），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -85.9%），过去两年Arcadia Biosciences, Inc.的营收复合增速更高（-4.5% vs -26.5%）
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
ACRS vs RKDA — 直观对比
营收规模更大
ACRS
是对方的1.4倍
$901.0K
营收增速更快
RKDA
高出60.1%
-85.9%
两年增速更快
RKDA
近两年复合增速
-26.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3M | $901.0K |
| 净利润 | — | $-1.3M |
| 毛利率 | 58.9% | 21.4% |
| 营业利润率 | — | -152.8% |
| 净利率 | — | -148.3% |
| 营收同比 | -85.9% | -25.8% |
| 净利润同比 | 79.5% | 67.1% |
| 每股收益（稀释后） | — | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACRSRKDA
| Q4 25 | $1.3M | $901.0K | ||
| Q3 25 | $3.3M | $1.3M | ||
| Q2 25 | $1.8M | $1.5M | ||
| Q1 25 | $1.5M | $1.2M | ||
| Q4 24 | $9.2M | $1.2M | ||
| Q3 24 | $4.3M | $1.5M | ||
| Q2 24 | $2.8M | $1.3M | ||
| Q1 24 | $2.4M | $987.0K |
净利润ACRSRKDA
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-14.6M | $856.0K | ||
| Q2 25 | $-15.4M | $-4.5M | ||
| Q1 25 | $-15.1M | $2.6M | ||
| Q4 24 | $-96.6M | $-4.1M | ||
| Q3 24 | $-7.6M | $-1.6M | ||
| Q2 24 | $-11.0M | $1.1M | ||
| Q1 24 | $-16.9M | $-2.4M |
毛利率ACRSRKDA
| Q4 25 | 58.9% | 21.4% | ||
| Q3 25 | 83.7% | 32.1% | ||
| Q2 25 | 71.0% | 43.4% | ||
| Q1 25 | 65.2% | 43.2% | ||
| Q4 24 | 92.3% | 31.9% | ||
| Q3 24 | 85.0% | 32.9% | ||
| Q2 24 | 77.4% | 51.5% | ||
| Q1 24 | 66.3% | 52.3% |
营业利润率ACRSRKDA
| Q4 25 | — | -152.8% | ||
| Q3 25 | -519.8% | -88.5% | ||
| Q2 25 | -1035.9% | -34.4% | ||
| Q1 25 | -1242.9% | 44.2% | ||
| Q4 24 | -1082.3% | -187.7% | ||
| Q3 24 | -240.9% | -114.5% | ||
| Q2 24 | -464.7% | — | ||
| Q1 24 | -789.4% | -160.9% |
净利率ACRSRKDA
| Q4 25 | — | -148.3% | ||
| Q3 25 | -443.0% | 65.7% | ||
| Q2 25 | -868.3% | -306.4% | ||
| Q1 25 | -1036.8% | 216.6% | ||
| Q4 24 | -1048.3% | -334.5% | ||
| Q3 24 | -174.6% | -104.9% | ||
| Q2 24 | -397.2% | 81.2% | ||
| Q1 24 | -706.5% | -245.5% |
每股收益（稀释后）ACRSRKDA
| Q4 25 | — | $-0.97 | ||
| Q3 25 | $-0.12 | $0.62 | ||
| Q2 25 | $-0.13 | $-3.26 | ||
| Q1 25 | $-0.12 | $1.90 | ||
| Q4 24 | $-1.21 | $-2.99 | ||
| Q3 24 | $-0.11 | $-1.18 | ||
| Q2 24 | $-0.15 | $0.78 | ||
| Q1 24 | $-0.24 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $103.1M | $4.1M |
| 总资产 | $160.5M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACRSRKDA
| Q4 25 | $20.0M | $4.6M | ||
| Q3 25 | $25.3M | $5.9M | ||
| Q2 25 | $25.4M | $4.4M | ||
| Q1 25 | $30.4M | $3.2M | ||
| Q4 24 | $24.6M | $4.2M | ||
| Q3 24 | $47.7M | $6.6M | ||
| Q2 24 | $22.8M | $8.1M | ||
| Q1 24 | $35.8M | $8.5M |
股东权益ACRSRKDA
| Q4 25 | $103.1M | $4.1M | ||
| Q3 25 | $120.1M | $5.4M | ||
| Q2 25 | $131.7M | $4.5M | ||
| Q1 25 | $144.1M | $8.9M | ||
| Q4 24 | $155.6M | $6.2M | ||
| Q3 24 | $130.2M | $10.3M | ||
| Q2 24 | $133.8M | $11.7M | ||
| Q1 24 | $142.0M | $10.6M |
总资产ACRSRKDA
| Q4 25 | $160.5M | $6.5M | ||
| Q3 25 | $175.5M | $8.6M | ||
| Q2 25 | $189.1M | $7.8M | ||
| Q1 25 | $198.1M | $13.0M | ||
| Q4 24 | $220.3M | $13.5M | ||
| Q3 24 | $182.4M | $15.2M | ||
| Q2 24 | $161.1M | $17.4M | ||
| Q1 24 | $174.1M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.1M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | $-47.2M | — |
| 自由现金流率自由现金流/营收 | -3646.6% | — |
| 资本支出强度资本支出/营收 | 8.6% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-81.3M | — |
8季度趋势，按日历期对齐
经营现金流ACRSRKDA
| Q4 25 | $-47.1M | $-861.0K | ||
| Q3 25 | $-10.9M | $-257.0K | ||
| Q2 25 | $-10.0M | $-2.0M | ||
| Q1 25 | $-13.1M | $-1.6M | ||
| Q4 24 | $-8.9M | $-2.2M | ||
| Q3 24 | $22.0M | $-1.8M | ||
| Q2 24 | $-12.3M | $-2.5M | ||
| Q1 24 | $-20.8M | $-3.2M |
自由现金流ACRSRKDA
| Q4 25 | $-47.2M | — | ||
| Q3 25 | $-11.0M | — | ||
| Q2 25 | $-10.0M | — | ||
| Q1 25 | $-13.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-12.3M | $-2.5M | ||
| Q1 24 | $-20.9M | $-3.2M |
自由现金流率ACRSRKDA
| Q4 25 | -3646.6% | — | ||
| Q3 25 | -332.1% | — | ||
| Q2 25 | -563.5% | — | ||
| Q1 25 | -900.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -446.0% | -188.3% | ||
| Q1 24 | -873.6% | -326.5% |
资本支出强度ACRSRKDA
| Q4 25 | 8.6% | 0.0% | ||
| Q3 25 | 0.7% | 0.0% | ||
| Q2 25 | 1.2% | 0.0% | ||
| Q1 25 | 3.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.5% | 0.2% | ||
| Q1 24 | 5.6% | 1.3% |
现金转化率ACRSRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
